A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC) Meeting Abstract
| Authors: | Kang, H.; Ahn, M. J.; Muzaffar, J.; Keam, B.; Bowles, D. W.; Wong, D. J. L.; Ho, A. L.; Kim, S. B.; Worden, F. P.; Yun, T.; Sari, S.; Conlan, M. G.; Hanna, G. J. |
| Abstract Title: | A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680301719 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.6020 |
| Notes: | Meeting Abstract: 6020 -- Meeting also held virtually -- Source: Wos |
